Project Grant HT94252510703
Award Date
7/1/25
Completion Date
6/30/29
Dollars Obligated
$1.3M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,498,368.00 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to elucidate molecular mechanisms of tumor-immune dynamics and evolution in response to radiation therapy for high- and very high-risk prostate cancer. The award, effective August 1, 2024 through July 31, 2027, will support cutting-edge...
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), was awarded a $577,094 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research aimed at "Redirecting Viral Immunity to Eradicate Low Tumor Mutation Burden Lung Cancers." The award period runs from Aug 31, 2023 to Aug 29, 2025. As a leading academic medical center and research institution, MGH utilizes its...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program provides $819,980.00 in funding to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on elucidating sex differences in melanoma tumorigenesis. The 3-year research project, beginning on August 15, 2024 and ending on August 14, 2027, aims to advance the understanding and treatment of this complex...
The Department of the Army Medical Command awarded a $1,644,309 project grant under the Military Medical Research and Development (CFDA 12.420) program to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on "FUNCTIONAL MOLECULAR NETWORKS MODIFYING HIF2A ACTIVITY IN VHL TUMORS." The award runs from February 1, 2025 to January 31, 2028. As a renowned academic medical center and major recipient of federal research funding,...
The General Hospital Corporation, doing business as Massachusetts General Hospital, received a $1,255,920 Project Grant award from the Department of the Army Medical Command on February 1, 2022, with a completion date of January 31, 2026. The grant was awarded under the Military Medical Research and Development program to support innovative biomedical research that transforms military and public health care. Specifically, the funding will support research to develop synergistic prostate-specific...
The Defense Health Agency awarded a $732,825 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) under the Military Medical Research and Development program (CFDA 12.420) for an extension of an artificial chromosome-based system as a novel delivery strategy for CAR-T cell therapy of ovarian cancer to human lymphocytes. This 3-year project, running from September 1, 2023 to August 31, 2026, aims to develop and validate new treatment approaches for ovarian cancer. As...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $730,033 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for research to develop therapies targeting AMH signaling within the ovarian cancer tumor microenvironment. The award has a performance period from April 15, 2024 to April 14, 2027. As part of its extensive biomedical research portfolio,...
The U.S. Defense Health Agency awarded a $653,928 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct a 3-year research project titled "TARGETING DENDRITIC CELLS IN BLADDER CANCER IMMUNOTHERAPY". The grant, funded under the Military Medical Research and Development program (CFDA 12.420), will support MGH's biomedical research, including clinical trials and laboratory studies, to develop new treatments and diagnostics for...
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), has been awarded a $1,000,236.00 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant, effective April 1, 2024 through March 31, 2028, will fund research to "UNLOCK THE CTDNA MUTATIONAL PATTERNS FOR EARLY CANCER DETECTION AND NONINVASIVE BIOMARKERS." As a leading academic medical center and research...
The federal Project Grant award with ID HT94252410711, titled "TARGETING HETEROGENEITY IN NF2-MUTANT TUMORS," was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The $1,568,220.00 grant, with a performance period from Sep 15, 2024 to Sep 14, 2027, was awarded to The General Hospital Corporation's Research Management Division, doing business as Massachusetts General Hospital (MGH). Through this funding, MGH will conduct...